TRAJENTA
As listed in the register: TRAJENTA
5 mg · tablet
- Prescription only
- Digestion, stomach, diabetes and nutrition
- Active substance
- Linagliptin
- Made by
- Boehringer Ingelheim (Canada) Ltd Ltee
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (Tradjenta). It describes the substance, not this exact product.
Linagliptin is an inhibitor of DPP-4, an enzyme that degrades the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP).
Thus, linagliptin increases the concentrations of active incretin hormones, stimulating the release of insulin in a glucose-dependent manner and decreasing the levels of glucagon in the circulation.
A small fraction of absorbed linagliptin is metabolized to a pharmacologically inactive metabolite, which shows a steady-state exposure of 13.3% relative to linagliptin.
Following administration of an oral [ 14 C]-linagliptin dose to healthy subjects, approximately 85% of the administered radioactivity was eliminated via the enterohepatic system (80%) or urine (5%) within 4 days of dosing.
A high-fat meal reduced C max by 15% and increased AUC by 4%; this effect is not clinically relevant.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2025-08-27
Safety of the active substance
From the US prescribing label for the same active substance (Tradjenta). It describes the substance, not this exact product.
- TRADJENTA is contraindicated in patients with hypersensitivity to linagliptin or any of the excipients in TRADJENTA, reactions such as anaphylaxis, angioedema, exfoliative skin conditions, urticaria, or bronchial hyperreactivity have occurred [see Warnings and Precautions (5.3) and Adverse Reactions (6) ].
- Hypersensitivity to linagliptin or any of the excipients in TRADJENTA ( 4, 5.3 )
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United States3 matching products
European UnionNo exact match for this strength and form
Spain21 matching products
- DONUMID 5 mg · comprimido recubierto con película
- ILINPRU 5 MG · comprimido recubierto con película
- LINAGLIPTINA ALTER 5 mg · comprimido recubierto con película
- LINAGLIPTINA AUROVITAS 5 mg · comprimido recubierto con película
- LINAGLIPTINA CINFA 5 mg · comprimido recubierto con película
- LINAGLIPTINA COMBIX 5 mg · comprimido recubierto con película
- LINAGLIPTINA DR REDDYS 5 mg · comprimido recubierto con película
- LINAGLIPTINA INTAS 5 mg · comprimido recubierto con película
Netherlands11 matching products
- Linagliptine Abdi 5 mg filmomhulde tabletten 5 mg · filmomhulde tablet
- Linagliptine Accord 5 mg 5 mg · filmomhulde tablet
- Linagliptine Aurobindo 5 mg 5 mg · filmomhulde tablet
- Linagliptine HCS 5 mg filmomhulde tabletten 5 mg · filmomhulde tablet
- Linagliptine Intas 5 mg filmomhulde tabletten 5 mg · filmomhulde tablet
- Linagliptine Macleods 5 mg filmomhulde tabletten 5 mg · filmomhulde tablet
- Linagliptine Sandoz 5 mg 5 mg · filmomhulde tablet
- Linagliptine Teva 5 mg 5 mg · filmomhulde tablet
SwitzerlandNo exact match for this strength and form
Details
| Made by | Boehringer Ingelheim (Canada) Ltd Ltee |
|---|---|
| Active substance | Linagliptin |
| Used in | Digestion, stomach, diabetes and nutrition |
| Strength | 5 mg |
| Form | tablet |
| Classification | A10BH05 · Digestion, stomach, diabetes and nutrition |
| Route | oral |
| Dispensing (as stated by the register) | PRESCRIPTION |
| Status | Marketed |
| Marketed | Yes, according to the register |
| DIN | 02370921 |
| DPD drug code | 85612 |
Source: Drug Product Database · 2026-09-30 · not reviewed by a clinician
Contains information licensed under the Open Government Licence – Canada. Reuse terms: Open Government Licence – Canada.